Vocimagene amiretrorepvec/extended release flucytosine: Phase Ib started

Tocagen began the open-label, U.S. Phase Ib Toca 6 trial to evaluate 14 mL IV Toca 511 daily for 3 consecutive days or 0.1-4 mL intralesional Toca 511 daily for 5 consecutive days in about 26 patients...